A Dose Finding Study of Intranasal Oxytocin in Behavioural Variant Frontotemporal Dementia (S29.007)

Finger, E; Jesso, Sarah; Rankin, Katherine; Boxer, Adam L.

doi:10.1212/wnl.78.1_meetingabstracts.s29.007

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In initial trials to determine safety and tolerability, patients with bvFTD or semantic dementia were given doses of either 24, 48, or 72 IU IN-OXT or placebo, twice daily for 1 week. All three doses were well tolerated by patients, and testing suggested beneficial effects of IN-OXT in treating behavioral symptoms, specifically apathy and empathy [ 193 , 194 ]. In a subsequent single-dose imaging study, 28 FTD patients received 72 IU IN-OXT or placebo prior to completing an fMRI combined facial expression mimicry test.…”

Section: Oxytocinmentioning

confidence: 99%

Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development

Bose

Quipildor

Ehrlich

et al. 2022

Cells

View full text Add to dashboard Cite

The central nervous system (CNS) has, among all organ systems in the human body, the highest failure rate of traditional small-molecule drug development, ranging from 80–100% depending on the area of disease research. This has led to widespread abandonment by the pharmaceutical industry of research and development for CNS disorders, despite increased diagnoses of neurodegenerative disorders and the continued lack of adequate treatment options for brain injuries, stroke, neurodevelopmental disorders, and neuropsychiatric illness. However, new approaches, concurrent with the development of sophisticated bioinformatic and genomic tools, are being used to explore peptide-based therapeutics to manipulate endogenous pathways and targets, including “undruggable” intracellular protein-protein interactions (PPIs). The development of peptide-based therapeutics was previously rejected due to systemic off-target effects and poor bioavailability arising from traditional oral and systemic delivery methods. However, targeted nose-to-brain, or intranasal (IN), approaches have begun to emerge that allow CNS-specific delivery of therapeutics via the trigeminal and olfactory nerve pathways, laying the foundation for improved alternatives to systemic drug delivery. Here we review a dozen promising IN peptide therapeutics in preclinical and clinical development for neurodegenerative (Alzheimer’s, Parkinson’s), neuropsychiatric (depression, PTSD, schizophrenia), and neurodevelopmental disorders (autism), with insulin, NAP (davunetide), IGF-1, PACAP, NPY, oxytocin, and GLP-1 agonists prominent among them.

show abstract

Section: Oxytocinmentioning

confidence: 99%